Ginsenoside Rh3

Cannabis sativa L.

Research on cannabidiol (CBD) in oncology has focused primarily on inflammatory signaling, oxidative stress, and cell survival pathways that cancers commonly rely on. Most mechanistic evidence comes from in vitro experiments and animal tumor models across colorectal, breast, lung, pancreatic, and glioma models. Human cancer-directed outcome data remain limited. The strongest clinical evidence relates instead to dose range, pharmacokinetics, hepatic monitoring, and drug–drug interaction patterns. Interpretation in oncology therefore rests largely on preclinical findings rather than established tumor response data.

Contain

Prevent dissemination, seeding, and metastatic establishment.

Starve

Weaken

Reduce tumor momentum by limiting expansion capacity, metabolic competence, and stress tolerance.

Attack

Apply controlled lethality once containment and weakening are stable.

Protect

Preserve host reserve so pressure remains selective and sustainable.

Evidence Summary

Human Data

There are currently no large randomized trials demonstrating tumor regression or survival benefit from CBD as a standalone anticancer therapy. Human oncology-specific outcome data remain limited.

Robust clinical data exist from prescription cannabidiol programs (e.g., epilepsy), which define dose ranges, plasma exposure levels, hepatic safety patterns, and drug–drug interaction risks.

Supportive-care trials involving cannabinoid preparations that include CBD (often combined with THC) report symptom-level benefits in some settings (advanced cancer pain; chemotherapy-induced nausea). Evidence specific to CBD-only preparations in oncology remains limited and mixed.

Animal Models

Animal tumor models report variable findings depending on tumor type, dose, and immune context.

In some xenograft studies, CBD administration has been associated with:

  • Reduced tumor growth
  • Increased oxidative stress within tumor tissue
  • Altered inflammatory signaling
  • Increased apoptosis-associated markers

Outcomes vary depending on tumor type, immune status, formulation, and dose.

In Vitro (Cell Models)

CBD has been extensively studied in cancer cell lines. Reported findings include:

  • Increased intracellular reactive oxygen species (ROS)
  • Activation of ER stress markers
  • Induction of intrinsic (mitochondrial) apoptosis markers
  • Modulation of autophagy signaling

Many in vitro experiments use micromolar concentrations that may exceed plasma concentrations achievable with standard oral retail dosing.

Pathway Interaction Profile

Key Pathways

Prevent Tumor Cell Shedding

NF-κB / TNF-α / IL-6 inflammatory axis (ID 56)

Preclinical investigations report reduced activity of inflammatory signaling pathways commonly implicated in tumor progression.

TGF-β context (ID ??)

Directionality depends on state and tissue context; interpret with care.

Neutralize CTCs in Transit

NRF2–GSH redox axis (ID 73)

In tumor cell models, CBD exposure has been associated with increased intracellular ROS and altered redox balance. Sustained oxidative stress has been linked to activation of apoptosis signaling in susceptible cells.

Intrinsic apoptosis (mitochondrial / Bcl-2) (ID 48)

Multiple studies describe activation of mitochondrial apoptosis signaling following CBD exposure in vitro.

ER stress & unfolded protein response (UPR) (ID 53)

Markers consistent with ER stress pathway activation have been identified in several tumor models.

Expanded Pathway Map

PK / Administration

Absorption

CBD is lipophilic and exhibits low, variable oral bioavailability due to first-pass hepatic metabolism. Plasma exposure increases when taken with dietary fat. Administration with food containing fat improves absorption consistency.

Clinical Dose Context

In clinical studies, CBD has been evaluated at approximately 10–20 mg/kg/day, and up to 25 mg/kg/day. For a 70 kg adult, this corresponds to roughly 700–1,400 mg per day. Most commercially available products provide substantially lower daily doses.

Metabolism

CBD is metabolized primarily by CYP3A4, CYP2C19, and CYP2C9. CBD can also inhibit these enzymes, potentially increasing circulating levels of medications that depend on these pathways for clearance.

Co-Dosing Considerations

Caution is warranted when combined with anticoagulants (e.g., warfarin), antiepileptics (e.g., clobazam), and chemotherapeutic or targeted agents metabolized via CYP3A4 or CYP2C19. Dose-dependent liver enzyme elevations have been observed, particularly at higher mg/kg ranges and in combination with other hepatically metabolized drugs.

Safety Profile

Human clinical data report:

  • Somnolence
  • Gastrointestinal disturbance
  • Dose-dependent elevations in ALT and AST
  • Clinically relevant CYP-mediated drug–drug interactions

Adverse effects appear dose-dependent and influenced by concurrent medications.

References
  1. EPIDIOLEX (cannabidiol) [prescribing information]. U.S. Food and Drug Administration; 2025. — URL required
  2. Grayson L, et al. An interaction between warfarin and cannabidiol. Epilepsy Behav Case Rep. 2017. — URL required
  3. [Systematic review authors]. Cannabinoid–anticoagulant interactions. Pharmacotherapy. 2023. — URL required
  4. Heider CG, et al. Mechanisms of Cannabidiol in Cancer Treatment. Int J Mol Sci. 2022. — URL required
  5. [Review authors]. CBD tumor biology review. [Journal]. [Year]. — URL required
Scroll to Top